Welcome to our dedicated page for 180 Life Sciences SEC filings (Ticker: ATNFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ATNFW SEC filings page aggregates regulatory documents related to the public warrants of 180 Life Sciences Corp. and the company’s broader corporate activities. 180 Life Sciences, described in its disclosures as a clinical-stage biotechnology company focused on inflammatory diseases, fibrosis and pain, files periodic and current reports that explain how its financings, governance decisions and strategic shifts affect both its common stock (ATNF) and warrants (ATNFW).
Recent Form 8-K filings detail significant capital markets transactions, including private placements of common stock and pre-funded warrants, the issuance of strategic advisor warrants, and a senior secured convertible note financing. These filings describe offering structures, warrant terms, conversion prices, registration rights agreements and related collateral arrangements, which are important for understanding dilution, potential share issuance and warrant overhang.
Other 8-Ks and proxy materials explain amendments to the company’s omnibus incentive plans, adoption of a 2025 option incentive plan, and an increase in authorized common shares. A series of filings in July and August 2025 describe the launch of a digital asset treasury strategy centered on acquiring Ether (ETH), the engagement of an asset manager, and the company’s ETH holdings, as well as the use of ETH and cash in connection with financings.
Filings dated August 2025 also document a name change from 180 Life Sciences Corp. to ETHZilla Corporation and the planned change of Nasdaq trading symbols from ATNF to ETHZ for common stock and from ATNFW to ETHZW for public warrants. These documents provide the authoritative record of the corporate transition and its impact on security identifiers.
On Stock Titan, users can access these SEC filings in one place, with AI-powered summaries that highlight key terms in 8-Ks, proxy statements and other disclosures. The platform is designed to help readers quickly identify material information about financings, warrant issuances, equity plans, governance changes and the evolution of the company’s capital structure that are relevant to the historical ATNFW warrants.
Blair Jordan, Chief Executive Officer of 180 Life Sciences Corp. (ATNFW), filed Schedule 13D/A Amendment No. 4 reporting that his beneficial ownership has dropped to 2,298,742 shares, or 1.5 % of the 154.0 M shares outstanding as of 5 Aug 2025, taking him below the 5 % reporting threshold on 4 Aug 2025.
Holdings include: (i) 160,000 directly held shares; (ii) 167,576 restricted shares issued 17 Jun 2025 and fully vested 12 Jul 2025; (iii) 410,000 vested options at $0.929; and (iv) irrevocable voting proxies over 1,561,166 additional shares. On 29 Jul 2025 Jordan’s consulting entity received a conditional grant of 3,908,986 options at $2.92, exercisable only after shareholder approval of the 2025 Supplemental Option Plan by 29 Jul 2026 and the closing of a related securities purchase agreement (completed 4 Aug 2025).
The amendment also records accelerated vesting of equity awards approved by the Board on 17 Jun and 12 Jul 2025. Jordan states the securities are held for investment purposes and, while he may buy or sell shares, he currently has no plans for mergers, asset sales, board changes or other corporate actions.
180 Life Sciences Corp. (symbol ATNFW) filed a Form S-8 to register 5,000,000 new common shares for equity compensation programs:
- 4,000,000 additional shares for the Fourth Amended & Restated 2022 Omnibus Incentive Plan
- 1,000,000 shares for the newly adopted 2025 Option Incentive Plan